It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Melissa L. Larson, MD

Patient Feedback
Specialty:
  • Hematology
  • Oncology, Medical
  • Internal Medicine
Board Certification:
  • Hematology
  • Medical Oncology
Faculty Rank: Associate Professor
Medical or Graduate Education: Rush Medical College
Residency: Rush University Medical Center - Internal Medicine
Fellowship: Rush University Medical Center - Hematology/Oncology
Clinical Expertise:
  • Anemia
  • Aplastic anemia
  • Chemotherapy
  • Hairy cell leukemia
  • Hodgkin lymphoma
  • Leukemias, acute and chronic
  • Myelodysplastic syndrome (MDS)
  • Myeloproliferative neoplasms
  • Non-Hodgkin lymphoma
Google Map
  • Consultants In Hematology
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 1010
  • Chicago, IL  60612
  • Phone: (312) 563-2320
  • Fax: (312) 563-2480
  • View Larger MapDriving Directions
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. IMPACT OF INSULIN-LIKE GROWTH FACTOR-I &amp; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS ON OUTCOMES IN ACUTE MYELOID LEUKEMIA.
    Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P
    Leuk. Lymphoma
    2015 Mar 4
    :1-27.
  2. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE
    Cancer
    2014 Sep 15
    :.
  3. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
    Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd.
    J Leukoc Biol. 2013
    2013 Jan
    93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7.
  4. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, et al.
    J Clin Oncol. 2012
    2012 Nov 19. [Epub ahead of print]
  5. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.
    Jagan S, Paganessi LA, Frank RR, Venugopal P, Larson M, Christopherson KW 2nd.
    Adv Hematol. 2012
    2012
    2012:727683. doi: 10.1155/2012/727683. Epub 2012 Sep 23.
  6. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.
    Leuk Lymphoma. 2011
    2011 Nov
    52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.
  7. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
    Larson ML, Venugopal P.
    Expert Opin Pharmacother. 2009
    2009 Jun
    10(8):1353-7. doi: 10.1517/14656560902997990. Review.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
92
Friendliness/courtesy of the care provider
4.9
Explanations the care provider gave you about your problem or condition
4.8
Concern the care provider showed for your questions or worries
4.8
Likelihood of your recommending this care provider to others
4.9
Care provider's efforts to include you in decisions about your treatment
4.8
Information the care provider gave you about medications
4.8
Instructions the care provider gave you about follow-up care
4.8
Your confidence in this care provider
4.9
Degree to which care provider talked with you using words you could understand
4.8
Amount of time the care provider spent with you
4.8
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.